Other Information .
−Removed: Conformed version of the Company’s Articles of Incorporation, as amended by that Certificate of
−Removed: Amendment previously filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K on November 8, 2019.
−Removed: Incorporated by reference to the designated exhibit of the Company’s
−Removed: Current Report on Form 10-Q filed on March 13, 2020.
−Removed: Corporate Bylaws, as amended by that Amendment No.
−Removed: 1 and Amendment No.
−Removed: Filed herewith
−Removed: Principal Executive Officer Certification required by Rules 13a-14 and 15d-14 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
−Removed: Filed herewith
−Removed: Principal Financial Officer Certification required by Rules 13a-14 and 15d-14 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
−Removed: Filed herewith
−Removed: Certification of Principal Executive Officer pursuant to 18 U.S.C.
−Removed: Section 1350, as adopted pursuant to Section 906 of Sarbanes Oxley Act of 2002.
−Removed: Filed herewith
−Removed: Certification of Principal Financial Officer pursuant to 18 U.S.C.
−Removed: Section 1350, as adopted pursuant to Section 906 of Sarbanes Oxley Act of 2002.
−Removed: Filed herewith
−Removed: Interactive Data Files for the Company’s Form 10-Q for the period ended January 31, 2021
−Removed: Submitted herewith.
+Added: of Amendment to Articles of Incorporation, as previously filed as Exhibit 99.1 to the Company’s
+Added: Current Report on Form 8-K on July 6, 2021
+Added: by reference to the designated exhibit of the Company’s Current Report on Form 10-K filed on August 10, 2021
+Added: of Change to Articles of Incorporation, as previously filed as Exhibit 99.1 to the Company’s
+Added: Current Report on Form 8-K on July 13, 2021
+Added: by reference to the designated exhibit of the Company’s Current Report on Form 10-K filed on August 10, 2021
+Added: 3 to PharmaCyte’s Bylaws, as previously filed as Exhibit 99.2 to the Company’s
+Added: Current Report on Form 8-K on June 4, 2021
+Added: by reference to the designated exhibit of the Company’s Current Report on Form 10-K filed on August 10, 2021
+Added: 4 to PharmaCyte’s Bylaws, as previously filed as Exhibit 99.2 to the Company’s
+Added: Current Report on Form 8-K on July 6, 2021
+Added: by reference to the designated exhibit of the Company’s Current Report on Form 10-K filed on August 10, 2021
+Added: Executive Officer Certification required by Rules 13a-14 and 15d-14as adopted pursuant to
+Added: Section 302 of the Sarbanes-Oxley Act of 2002
+Added: Executive Officer Certification required by Rules 13a-14 and 15d-14as adopted pursuant to
+Added: Section 302 of the Sarbanes-Oxley Act of 2002
+Added: Certification
+Added: of Principal Executive Officer pursuant to 18 U.S.C.
+Added: Section 1350, as adopted pursuant to
+Added: Section 906 of Sarbanes Oxley Act of 2002
+Added: Certification
+Added: of Principal Executive Officer pursuant to 18 U.S.C.
+Added: Section 1350, as adopted pursuant to
+Added: Section 906 of Sarbanes Oxley Act of 2002
+Added: Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
+Added: Inline XBRL Taxonomy Extension Schema Document
+Added: Inline XBRL Taxonomy Extension Calculation Linkbase Document
+Added: Inline XBRL Taxonomy Extension Definition Linkbase Document
+Added: Inline XBRL Taxonomy Extension Label Linkbase Document
+Added: Inline XBRL Taxonomy Extension Presentation Linkbase Document
+Added: Cover Page Interactive Data File (formatted in IXBRL, and included in exhibit 101).
Pursuant to the requirements of the Securities
−Removed: Exchange Act of 1934, as amended, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto
−Removed: duly authorized.
+Added: Exchange Act of 1934, as amended, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly
PharmaCyte Biotech, Inc.
−Removed: March 12, 2021
+Added: September 14, 2021
/s/ Kenneth L.
1 unchanged sentence
(Duly Authorized Officer and Principal Executive Officer)
−Removed: March 12, 2021
+Added: September 14, 2021
/s/ Carlos A.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.